Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9499545 | ABBVIE | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Nov, 2031
(7 years from now) | |
US8754096 | ABBVIE | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Jul, 2032
(8 years from now) | |
US9850246 | ABBVIE | Process for making CGRP receptor antagonists |
Mar, 2033
(8 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10117836 | ABBVIE | Tablet formulation for CGRP active compounds |
Jan, 2035
(10 years from now) |
Qulipta is owned by Abbvie.
Qulipta contains Atogepant.
Qulipta has a total of 4 drug patents out of which 0 drug patents have expired.
Qulipta was authorised for market use on 28 September, 2021.
Qulipta is available in tablet;oral dosage forms.
Qulipta can be used as preventive treatment of migraine in adults.
Drug patent challenges can be filed against Qulipta from 28 September, 2025.
The generics of Qulipta are possible to be released after 30 January, 2035.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-909) | Apr 17, 2026 |
New Chemical Entity Exclusivity(NCE) | Sep 28, 2026 |
Drugs and Companies using ATOGEPANT ingredient
NCE-1 date: 28 September, 2025
Market Authorisation Date: 28 September, 2021
Treatment: Preventive treatment of migraine in adults
Dosage: TABLET;ORAL